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Background: Health economic evaluations support the health care decision-making process by providing
information on costs and consequences of health interventions. The quality of such studies is assessed by health
economic evaluation (HEE) quality appraisal instruments. At present, there is no instrument for measuring and
improving the quality of such HEE quality appraisal instruments. Therefore, the objectives of this study are to
establish a framework for assessing the quality of HEE quality appraisal instruments to support and improve their
quality, and to apply this framework to those HEE quality appraisal instruments which have been subject to more
scrutiny than others, in order to test the framework and to demonstrate the shortcomings of existing HEE quality
appraisal instruments.
Methods: To develop the quality assessment framework for HEE quality appraisal instruments, the experiences of
using appraisal tools for clinical guidelines are used. Based on a deductive iterative process, clinical guideline
appraisal instruments identified through literature search are reviewed, consolidated, and adapted to produce the
final quality assessment framework for HEE quality appraisal instruments.
Results: The final quality assessment framework for HEE quality appraisal instruments consists of 36 items organized
within 7 dimensions, each of which captures a specific domain of quality. Applying the quality assessment
framework to four existing HEE quality appraisal instruments, it is found that these four quality appraisal instruments
are of variable quality.
Conclusions: The framework described in this study should be regarded as a starting point for appraising the
quality of HEE quality appraisal instruments. This framework can be used by HEE quality appraisal instrument
producers to support and improve the quality and acceptance of existing and future HEE quality appraisal
instruments. By applying this framework, users of HEE quality appraisal instruments can become aware of
methodological deficiencies inherent in existing HEE quality appraisal instruments. These shortcomings of existing
HEE quality appraisal instruments are illustrated by the pilot test.Background
The optimal allocation of scarce resources for the pro-
duction of health benefits to society requires best evi-
dence of cost-effectiveness, and is relevant to any
decision in health care. Health economic evaluations
support the health care decision-making process by
providing information on costs and consequences of
health interventions. For example, the NHS EconomicCorrespondence: astrid-langer@gmx.de
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ity assessed economic evaluations, the results of which
are increasingly used for pricing and reimbursement
decisions.
To be useful, health economic evaluation studies
should be methodologically comparable, of high quality
(e.g., in terms of transparency, quality of data sources,
completeness of documentation), and relevant for the
health care decision context. However, the quality of the
conduct and reporting in such studies varies [1]. Health
economic evaluation studies are heterogeneous with re-
spect to purposes, conceptual and measurement issues,
and value judgments leading to problems with compar-
ability and suboptimal delivery of care. To ensure thehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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comparison and transferability of economic evaluation
results, methodological standards for health economic
evaluations have been established [2]. Besides the pur-
poses of setting methodological and ethical standards,
such standards are also used as a formal requirement
prior to reimbursement [3].
There are different instruments to guide the quality
assessment of health economic evaluations. Among
these health economic evaluation (HEE) quality appraisal
instruments, considerable agreement exists on the ter-
minology of economic evaluation, the importance of
considering alternatives, the need for specifying the ana-
lytical viewpoint, the superiority of incremental analysis,
the principal need for discounting costs and benefits,
and the importance of conducting a sensitivity analysis
[2]. Besides particular methodological issues such as
inclusion of indirect costs or choice of discount rate,
differences between these HEE quality appraisal instru-
ments refer to the level of aggregation. For instance,
the International Society for Pharmacoeconomics and
Outcomes Research (ISPOR) has set up several task
forces for specific elements of an economic evaluation,
e.g., the ISPOR Task Force on Good Research Practices
for Modeling Studies [4].
As methods of health economic evaluation mature
over time, it is also important to appraise and monitor
the quality of these HEE quality appraisal instruments
which are used by researchers, journals, institutions and
governments throughout the world to assess new health
technologies and allocate resources. To date, tools for
comparing, measuring, and improving the quality of
HEE quality appraisal instruments have not been devel-
oped. Therefore, the objectives of this study are to: es-
tablish a framework for assessing the quality of HEE
quality appraisal instruments in order to support and
improve their quality; apply this quality assessment
framework to those HEE quality appraisal instruments
which have been subject to relatively more scrutiny than
others, in order to test the framework and to demon-
strate the shortcomings of existing HEE quality appraisal
instruments.
Methods
Before developing a framework for quality assessment of
HEE quality appraisal instruments, it might be prudent
to review experiences regarding other applications of
quality appraisal instruments. The obvious locus for
such a review is appraisal tools for clinical guidelines.
To identify potentially relevant clinical guideline ap-
praisal instruments, the following electronic databases
were searched from inception to October 2010: PubMed,
RePEc, and Web of Science. The literature search used
the following search terms (including synonyms andclosely related words): “clinical guidelines” combined
with “appraisal”, “instrument”, and “quality”. Only publi-
cations in English, French, or German were considered.
Further publications were retrieved by citation tracking,
using the “related citations” function in PubMed and
Web of Science, hand searching the journals “Inter-
national Journal of Technology Assessment in Health
Care”, “International Journal for Quality in Health Care”,
and “Quality & Safety in Health Care” from 2000 to
2010, and searching relevant websites. A total of 14 rele-
vant guideline appraisal instruments were retrieved by
the search process (see Additional file 1), which are
described in Table 1.
However, it was not intended to provide a systematic
review of appraisal tools for clinical practice guideline
evaluation. Therefore, the interested reader is referred to
the reviews by Vlayen et al. [19] and Graham et al. [20],
which were identified by the literature search on clinical
guideline appraisal instruments and provide a detailed
description and comparison of clinical practice guideline
appraisal instruments. These systematic reviews were
used to inform the framework development.
Based on a deductive iterative process, the clinical
guideline appraisal instruments identified were reviewed,
consolidated, and adapted. For this purpose, all ques-
tions/statements included in these instruments were
listed to exclude double counting. For inclusion in the
final framework, the questions/statements were required
to have the following characteristics:
○ Generally and internationally accepted
○ Relevant to the realm of health economic evaluation
○ Distinguishable from other questions/statements
(i.e., the questions/statements selected for final
inclusion should overlap as little as possible)
The questions/statements identified by this meth-
od were thematically grouped to devise the final quality
assessment framework for HEE quality appraisal
instruments.
In order to test the framework and demonstrate the
shortcomings of existing HEE quality appraisal instru-
ments, the framework developed was applied to those
HEE quality appraisal instruments which have been sub-
ject to relatively more scrutiny than others. Using a simi-
lar search process, HEE quality appraisal instruments
were determined possibly relevant if they provided expli-
cit criteria against which the quality of economic evalua-
tions could be appraised. Because of regional, cultural,
institutional, or political preferences and interests,
country-specific guidelines were not considered for in-
clusion. Instruments assessing the transferability of
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A1. The reasons for developing the
guideline are stated
A2. The overall objective of the
guideline is described
A3. The health economic studies for which
the guideline was designed are stated
A4. The target audience of the guideline
is characterized
A5. The time frame to which the guideline
is meant to apply is specified
B. Stakeholder
involvement
B1. The guideline development group consists
of individuals from all relevant disciplines
B2. Conflicts of interest of guideline
development group members have been
recorded and addressed
B3. The views and preferences of the target




C1. The members of the guideline development
group and their affiliations are stated
C2. The methods used for literature search
are specified
C3. The sources of evidence on which the
guideline is based are described
C4. The criteria for selecting existing evidence
are described
C5. The methods for formulating the items
are specified
C6. The methods used to reach consensus
are specified
C7. The date for reviewing/updating the
guideline is stated
C8. The guideline is valid in terms of:
C8a. Content (internal) validity
C8b. Criterion (external) validity




D1. The process of guideline development
is documented
D2. The guideline has been externally reviewed
by experts prior to its publication
D3. The guideline has been piloted/pretested
among the target audience




D4d. Internal consistency reliability
E. Clarity of
presentation
E1. The items of the guideline are specific and
clearly worded
E2. The items of the guideline are clearly
presented and user friendly
Table 2 Framework for quality assessment of HEE quality
appraisal instruments (Continued)
E3. The guideline can be used in a
straightforward manner
E4. Key items are easily identifiable
F. Applicability F1. The guideline provides a standard
reporting format
F2. The guideline gives a detailed assessment
instruction
F3. The guideline presents items of
methodological quality and transparency
F4. The guideline uses a quality score
F5. The strengths and limitations of the
guideline are specified
G. Evaluation G1. The methods for evaluating the guideline
are described
G2. The adherence to the guideline by the
target audience is described
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Framework for quality assessment of HEE quality
appraisal instruments
The framework consists of 36 items organized within 7
dimensions, each of which captures a specific domain of
quality: Dimension A (“purpose and scope”, items A1-
A5), Dimension B (“stakeholder involvement”, items
B1-B3), Dimension C (“rigor of development process/
validity”, items C1-C8c), Dimension D (“reliability/
reproducibility”, items D1-D4d), Dimension E (“clarity
of presentation”, items E1-4), Dimension F (“applicabil-
ity”, items F1-F5), Dimension G (“evaluation”, items G1-
G2). The quality assessment framework is presented in
Table 2.
Application of the quality assessment framework
To test the established framework and to demon-
strate the shortcomings of existing HEE quality ap-
praisal instruments, four well-known, often-cited, and
widely-used HEE quality appraisal instruments, which
have been subject to relatively more scrutiny than
most others, were selected: the Quality of Health
Economic Studies (QHES) instrument developed by
Chiou et al. [21], the British Medical Journal (BMJ)
guidelines for economic submissions established by
Drummond and Jefferson on behalf of the BMJ Eco-
nomic Evaluation Working Party [22], the Consensus
on Health Economic Criteria (CHEC) list devised by
Evers et al. [23], and the Good Practice Guidelines
for Decision-Analytic Modeling accomplished by Phi-
lips et al. [24].
The BMJ list, the CHEC list, and the Philips list were
chosen because they are recommended by the Cochrane
Handbook for Systematic Reviews of Interventions [25]














1 QHES instrument [21].
2 BMJ guidelines [22].
3 CHEC list [23].
4 Philips guidelines [24].
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health economic evaluation studies. In the chapter
related to systematic reviews of economic evaluations,
the Centre for Reviews and Dissemination’s guidance for
undertaking reviews in health care [26] also refers to the
BMJ list and the Philips list as instruments to assess the
quality of economic evaluations. The QHES instrument
was selected because it is an example of a quality scoring
system which has been the subject of controversy in the
literature.
As can be seen in Table 3, the BMJ list and the QHES
instrument are broader and more comprehensive than
the other two quality appraisal instruments: this is be-
cause the Philips list is solely designed for model-based
economic evaluations and the CHEC list is only
intended for undertaking systematic reviews of trial-
based economic evaluations. In Table 4, the main char-
acteristics of the HEE quality appraisal instruments are
provided.
Pilot review of the quality assessment framework
The experiences of applying the quality assessment
framework to the HEE quality appraisal instruments are
presented in Table 5.
The quality dimension of “purpose and scope” (dimen-
sion A) is fulfilled by all HEE quality appraisal instru-
ments, even though not all items are explicitly
described. In terms of the quality dimension of “stake-
holder involvement” (dimension B), only Evers et al.
(CHEC list, [23]) do not declare whether they have any
conflicts of interest. Furthermore, at none of the differ-
ent HEE quality appraisal instrument development
stages were all the key professionals (e.g., economists,
clinicians, epidemiologists, and statisticians) involved.
However, all the quality appraisal instruments used
methods to ensure that the perspectives of the target
audience informed the development process (e.g., by
participation on the development group, or by external
review of drafts of the appraisal instruments). The main
differences in the quality of the four HEE quality ap-
praisal instruments relate to the quality dimension of“rigor of development process/validity” (dimension C).
Especially with the BMJ list, the different stages of the
development process are not reported. Moreover, as
methodology advances, the date for updating the ap-
praisal instrument should be stated. Only Philips et al.
[24] refer to the need for periodic updates, but when
these should take place remains unclear. The lack of for-
mal validity is one of the main limitations of all four
quality appraisal instruments. Only the QHES instru-
ment was formally validated in terms of construct valid-
ity [21]. Other limitations refer to the quality dimension
of “reliability/reproducibility” (dimension D). As men-
tioned before, the development process of the BMJ list is
not documented. All four HEE quality appraisal instru-
ments were published in peer-reviewed journals and,
hence, external reviewers were involved in appraisal in-
strument development during the generic review
process. However, in order to develop the BMJ list and
the Philips list, additional external experts were con-
vened to discuss drafts of these quality appraisal instru-
ments. In addition, provided that external reviewers
should not have been involved in developing the ap-
praisal instrument, the QHES instrument and the CHEC
list have not been externally reviewed before their publi-
cation (certainly, except for the review process). For the
appraisal instrument to be effective with regard to reli-
ability and reproducibility, it also needs to be piloted/
pretested among the target audience. Only the QHES in-
strument was pretested among 60 experts in the field of
health economics, who evaluated the methodological
quality of three health economic analyses, first on a vis-
ual analog scale, and then using the grading system. In
respect of the quality dimension of “clarity of presenta-
tion” (dimension E), the appraisal instruments estab-
lished by Philips et al. [24] and the grading system
developed by Chiou et al. (QHES instrument, [21]) do
not provide specific and unambiguous items in those
cases where more than one question refers to the same
criterion, resulting in ambivalent assessments. Addition-
ally, on account of the rather technical nature of the
questions provided by Philips et al. [24], these are only
suitable for specialist readers with expertise in the field
of decision-analytic modelling and with knowledge of
the disease area. Philips et al. [24] state that without that
knowledge, it is a complex matter to decide whether all
structural assumptions are justified, or whether all feas-
ible and practical options have been evaluated. Further,
because of the problem with the interpretation of the
term “justified” or “appropriate”, it might be difficult to
use these four quality appraisal instruments in a straight-
forward manner. Some items/questions are highly
dependent on the judgment of the respective user and
thus have an unavoidable element of subjectivity. For ex-
ample, based on a comparison of three instruments for
Table 4 Main characteristics of the four selected HEE quality appraisal instruments
QHES instrument [21] BMJ guidelines [22] CHEC list [23] Philips guidelines [24]





Evers et al. 2005; International
Journal of Technology
Assessment in Health Care
Philips et al. 2006;
Pharmacoeconomics
Affiliation of authors Academia and industry Academia Academia Academia
Published in a
peer-reviewed journal
Yes Yes Yes Yes
Number of references 35 48 30 22
Purpose To provide a grading system




To develop a generally





To identify, review, and consolidate
currently available guidelines in
order to establish a synthesized
and consistent quality assessment
framework for decision analytic
models
Development process Selection of criteria from 19
existing guidelines; Use of a
conjoint analysis survey of
120 international experts to
estimate weights for each
criterion
Not specified Selection of items from 15
existing guidelines; Use of a
Delphi panel consisting of
23 international experts to
generate the final criteria list
Selection and formulation of items
by reviewing and consolidating 15
existing guidelines for good
practice in decision-analytic
modeling in HTA




After peer review Before, during, and after
peer review





conduct a systematic review
of trial-based economic
evaluations























16 questions which should
be asked when appraising
the quality of health
economic evaluations
Ten sections under the three
headings of study design,
data collection, and analysis
and interpretation of results:





adjustments for timing of
costs and benefits, allowance
for uncertainty, and
presentation of results
19 questions which should
be asked when appraising
the quality of health
economic evaluations in
systematic reviews
15 sections under the three key
themes of structure, data, and
consistency: statement of decision
problem/objective, statement of
scope/ perspective, rationale for
structure, structural assumptions,
strategies/comparators, model
type, time horizon, disease
states/pathways, cycle length,
data identification, pre-model
data analysis, data incorporation,











Use of a quality score Yes No No No
Assessment instruction No Yes Yes: http://www.beoz.
unimaas.nl/chec/
Yes
Pilot test of the
guideline
Yes: Ofman et al. [31] Not specified Yes, but no details given Yes
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(BMJ list, CHEC list, and QHES instrument) Gerkens
et al. [27] found that the reviewer has a greater influence
on the results of the quality assessment than theappraisal instrument itself. Another problem within this
dimension concerns the operationalization of the ques-
tions. Chiou et al. (QHES instrument, [21]) and Evers
et al. (CHEC list, [23]) provide questions in a yes/no
Table 5 Application of the quality assessment framework to the four selected HEE quality appraisal instruments
Dimension Item QHES instrument [21] BMJ guidelines [22] CHEC list [23] Philips guidelines [24]
A. Purpose and scope A1 YES YES YES YES
A2 YES YES YES YES
A3 YES YES YES YES
A4 YES YES YES YES
A5 YES YES YES YES
B. Stakeholder involvement B1 NO NO NO NO
B2 YES YES NO YES
B3 YES YES YES YES
C. Rigor of development
process/validity
C1 YES PARTIALLY YES YES
C2 YES NO YES YES
C3 YES NO YES YES
C4 YES NO NO YES
C5 YES NO YES YES
C6 YES NO YES YES
C7 NO NO NO NO
C8
C8a NO NO NO NO
C8b NO NO NO NO
C8c YES NO NO NO
D. Reliability/reproducibility D1 YES NO YES YES
D2 NO YES NO YES
D3 YES NO NO NO
D4
D4a NO NO NO NO
D4b NO NO NO NO
D4c NO NO NO NO
D4d NO NO NO NO
E. Clarity of presentation E1 NO YES YES NO
E2 YES YES YES NO
E3 NO NO NO NO
E4 YES NO NO NO
F. Applicability F1 YES YES YES YES
F2 NO YES YES YES
F3 YES YES YES YES
F4 YES NO NO NO
F5 YES NO YES YES
G. Evaluation G1 NO YES YES YES
G2 NO NO NO NO
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may not be applicable to the study context. Because of
the weighting of the criteria, only the key items of the
QHES instrument can be easily identified. Regarding the
quality dimension of “applicability” (dimension F), all
appraisal instruments provide a standard reportingformat and present items of methodological quality and
transparency. All but the QHES instrument give detailed
assessment instructions (to a greater or lesser extent)
and all appraisal instruments except for the BMJ list spe-
cify their strengths and limitations. The QHES instru-
ment is the only quality appraisal instrument to use a
Langer BMC Health Services Research 2012, 12:253 Page 9 of 11
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“evaluation” (dimension G), all but the QHES instru-
ment describe the evaluation methods. However, none of
the instruments describes the extent of adherence by the
target audience.
Discussion
At present, there is no common instrument for measur-
ing and improving the quality of HEE quality appraisal
instruments. A quality assessment framework for HEE
quality appraisal instruments was developed to support
and improve their quality. It permits not only the assess-
ment of their quality but also the recognition of the
most urgent adjustments needed to improve their qual-
ity. Applying the quality assessment framework to four
existing HEE quality appraisal instruments, it was found
that these quality appraisal instruments are of variable
quality.
Moreover, the HEE quality appraisal instruments have
other limitations. The CHEC list established by Evers
et al. [23] consists of a minimum set of items and is
intended only for full economic evaluations based on
clinical trials. In order to appraise the overall methodo-
logical quality of trial-based economic evaluations, the
authors point out that their list should be used in com-
bination with existing instruments for assessing the
quality of clinical trials [23]. In systematic reviews in-
cluding trial-based and model-based economic evalua-
tions, the CHEC list should be combined with issues
relevant to modelling studies such as structural assump-
tions. Therefore, in a systematic review [28], the ap-
praisal instruments developed by Philips et al. [29] were
used as a complement to the CHEC list. Another limita-
tion concerns the items included in the CHEC list. As
these items should deliver insight into the quality of eco-
nomic evaluation studies, most of them are rather sub-
jective, which is a challenge for the inter-rater reliability
[23]. However, formularies and HTAs would in fact need
some flexibility to make their own best decisions for
their patients. The subjective judgment generally inher-
ent in quality assessment is a particularly fundamental
problem for the Philips guidelines [24]. Additionally, be-
cause of the combination of transparency and quality
aspects in the same question, the Philips guidelines pro-
duce ambivalent quality assessments. By contrast, other
research groups provide quality appraisal instruments
that differentiate between these two issues [30]. Further-
more, because of the scope of the Philips list, it should
be used in conjunction with more general quality assess-
ment instruments for health economic evaluation (e.g., the
BMJ list) [24]. The quality appraisal instrument devised
by Philips et al. [24] include dimensions of methodo-
logical quality corresponding to rationales for structure,
structural assumptions, disease states/pathways, cyclelength, and internal consistency. This is due to the fact
that this HEE quality appraisal instrument is specific for
decision-analytic models, and, thus, has a more tech-
nical character than the other three HEE quality ap-
praisal instruments. Therefore, the Philips list does not
highlight the importance of discounting, the superiority
of incremental analysis, and the measurement and
valuation of costs. However, in their version published
in 2004, Philips et al. [29] point out that “costing and
discounting methods should accord with standard
guidelines for economic evaluation”. Due to limitations
in reporting, the quality of the BMJ list in particular was
difficult to assess. In contrast to the other three quality
appraisal instruments, the QHES instrument provides a
grading system, but the advantage of scoring methods is
questionable.
To date, relatively little empirical research has been
undertaken in order to investigate the influence of deci-
sions to include only economic evaluations of high qual-
ity on the results of a critical assessment of health
economic evaluations. However, such lessons can be
obtained from the experiences made with quality scores
for clinical studies. Using 25 different quality assessment
scales to identify high-quality clinical trials, Jüni et al.
[32] show that the conclusions of meta-analytic studies
of randomized clinical trials might be affected by the
type of quality assessment scale used. They consider the
use of grading systems to be problematic, and thus they
recommend that relevant methodological issues should
be appraised individually. In a review, Moher et al. [33]
use the same 25 scales to show differences in scale de-
velopment. As these differences can result in important
differences in quality assessment, they recommend that
meta-analyses of randomized clinical trials should be
undertaken with and without assessing quality. Based on
these experiences, it is not recommended to select eco-
nomic evaluations on the basis of their quality scores, as
proposed by Chiou et al. (QHES instrument, [21]. In
general, a corresponding NHS EED structured abstract
[34] consisting of “subject of study”, “key elements of
study”, “details about clinical evidence”, “economic ana-
lysis”, “results”, “critical commentary”, “implications”,
and “other publications of related interest” might en-
hance quality assessment of all types of full health eco-
nomic evaluation informed by HEE quality appraisal
instruments, because these abstracts provide critical ap-
praisal of methodological quality on the basis of the
same quality dimensions as included in the quality ap-
praisal instruments [25]. In their study, Thurston et al.
[35] found that decision-makers in health care need an
initial screen of economic evaluation results provided by
a critical descriptive summary or a score, plus a short
abstract to gather more information on the quality and
relevance of economic evaluation results. However, how
Langer BMC Health Services Research 2012, 12:253 Page 10 of 11
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methodological quality is an unresolved issue which
requires further research.
Conclusions
The framework described in this study should be
regarded as a starting point for assessing the quality of
HEE quality appraisal instruments. This framework can
be used by quality appraisal instrument producers to
support and improve the quality and acceptance of exist-
ing and future HEE quality appraisal instruments. By ap-
plying this framework, users of HEE quality appraisal
instruments can become aware of methodological defi-
ciencies inherent in existing quality appraisal instruments,
as illustrated by the pilot test. As the development of HEE
quality appraisal instruments is a dynamic and interactive
process, and as methodology advances, a continual update
of existing quality appraisal instruments is needed.
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